Aurora Spine Corporation Announces FDA 510(k) Clearance for Its SiLO TFX™ MIS Sacroiliac Joint Fusion System, The Canadian Business Journal

CARLSBAD, Calif., Oct. 4, 2022 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASPF) is a developer of innovative medical devices that deliver improvements. is a designer and manufacturer. As a result of spinal surgery, today we announced that we have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our patented minimally invasive SiLO TFX MIS sacroiliac arthrodesis system. Additional details regarding the SiLO TFX MIS sacroiliac arthrodesis system will be disclosed by the company in a more detailed press release issued on October 6, 2022.

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.

Forward-Looking Statements

This news release contains material known and unknown risks beyond Aurora Spine’s control, including but not limited to those described in “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information.” and includes forward-looking information including uncertainties.n” are set forth in Aurora Spine’s final prospectus (collectively, the “Forward-Looking Information”). Forward-looking information in this news release includes information regarding the proposed use and success of the company’s products in surgical procedures. Aurora Spine advises investors in Aurora Spine securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected by the forward-looking statements contained in this news release. I warn you.Statements that express or involve expectations, beliefs, plans, objectives, assumptions, or discussions of future events or performance are not historical facts, may be forward-looking, and may not give rise to actual results or results. may involve significant estimates, assumptions, and uncertainties that differ unilaterally from them expressed in such forward-looking statements. There is no guarantee that the expectations set forth herein will prove correct. Accordingly, future investors should not place undue reliance on these forward-looking statements. These statements are current as of the date of this press release and Aurora Spine undertakes no obligation to update or revise them to reflect new events or circumstances.

contact:

Aurora Spine Corporation

Trent Northcutt

President and Chief Executive Officer

(760) 424-2004

Chad Close

CFO

(760) 424-2004

www.aurora-spine.com

Adam Lowensteiner

Lytham Partners LLC

Phoenix | Phoenix | New York

Phone: 646-829-9700

[email protected]

Neither TSX Venture Exchange nor its regulated service providers (as those terms are defined in the TSX Venture Exchange Policy) are responsible for the adequacy or accuracy of this release.

CBJ Newsmaker